hla-a1-binding mage-1/mage-3 multipeptide-pulsed autologous dendritic cell vaccine
Cell therapyexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2002 (NCT01082198)
Timeline
2000s
- Jan 1, 2002
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Melanoma-associated antigen 3Immunity, active
immunity, active - mage3
- Melanoma-associated antigen 1Immunity, active
immunity, active - mage1
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- hla-a1-binding mage-1/mage-3 multipeptide-pulsed autologous dendritic cell vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01082198 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2002 | Maria Sklodowska Curie Children's Hospital |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Maria Sklodowska Curie Children's Hospital | Academic/Hospital | 1 | 1 | 1 | 2002 |
1 organizations
Page 1 / 1